CAR-T cell therapy research

EphA2 and Phosphoantigen-Mediated Selective Killing of Medulloblastoma by γδT Cells Preserves Neuronal and Stem Cell Integrity

This study shows that γδT cells can selectively kill medulloblastoma cells without harming neurons or stem cells, offering a safer and more effective treatment option.

Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

Cysteine-Engineered CAR-T Cells to Counter Antigen Escape in B Cell Lymphoma

This paper introduces cysteine-engineered CAR-T cells that target both conventional antigens and altered redox states in B cell lymphoma, reducing the risk of antigen escape.

Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALL

This study characterizes CAR+ T-cell subsets and immune system dynamics in pediatric BCP-ALL patients treated with tisagenlecleucel, finding correlations between immune cell changes and cytokine release syndrome.

Single-cell-guided identification of logic-gated antigen combinations for designing effective and safe CAR therapy

This paper introduces LogiCAR designer, a computational method using single-cell transcriptomics to identify logic-gated antigen combinations for CAR therapy, showing improved efficacy and safety compared to existing approaches.

Total body irradiation primes CD19-directed CAR T cells against large B-cell lymphoma

This study shows that total body irradiation before CAR T cell infusion enhances their effectiveness against large B-cell lymphoma by improving cytotoxicity and survival outcomes.

The 1000+ mouse project: large-scale spatiotemporal parametrization and modeling of preclinical cancer immunotherapies

The paper introduces maRQup, a method for analyzing bioluminescent tumor images in over 1,000 mice, showing CD28 CAR-T cells initially control tumors better than 4-1BB CAR-T cells, which reduce relapse frequency.

T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H

The paper identifies T-cell receptors targeting KRAS Q61H neoantigen in NSCLC patients using antigen-agnostic screening and demonstrates their reactivity and potential for adoptive cell therapy.

Designed allosteric biosensors for engineered T cell therapy of cancer

This paper develops T-SenSER, a synthetic biosensor for T cells that enhances anti-tumor responses by sensing TME factors like VEGF and CSF1, showing improved efficacy in lung cancer and multiple myeloma models.

CSPG4-targeting CAR-macrophages inhibit melanoma growth

This study engineers CSPG4-targeting CAR-macrophages that inhibit melanoma growth in vitro and in vivo, showing promise for solid tumor immunotherapy.

Rational redesign of antigen binding domain improves in vivo efficacy of CD22-CAR T cells

This study improves the in vivo efficacy of CD22-targeted CAR T cells by optimizing the balance between binding affinity and tonic signaling through rational redesign of the antigen binding domain.

Engineering CD3 Subunits with Endoplasmic Reticulum Retention Signal Facilitates Allogeneic CAR T Cell Production

This paper develops a method to reduce TCR expression in CAR T cells using engineered CD3 subunits with an endoplasmic reticulum retention signal, avoiding genome editing and enabling safer allogeneic CAR T cell production.

The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicities

This study identifies a Th1/Th17 imbalance driven by IFN{gamma} that causes cytokine release syndrome and neutropenia in CAR-T therapy, suggesting IFN{gamma} blockade as a potential treatment.

Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence

This study screens CAR-T designs in nonhuman primates and identifies MyD88-CD40 costimulatory domains as superior for proliferation, trafficking, and persistence.

The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies.

This study identifies that the costimulatory domain of CD19-CAR-T cells influences resistance development in B-cell malignancies by affecting CD19 loss and antigen escape.

RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant B-Cell Lymphoma

Targeting Anti-HLA Class I and II Antibodies with CAR-B Cell Therapy: A Novel Strategy to Mitigate Graft Rejection and Platelet Refractoriness

This paper proposes CAR-B cell therapy targeting anti-HLA Class I and II antibodies to reduce graft rejection and transfusion reactions by specifically neutralizing these antibodies and T cell responses.

Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells

This study introduces hydroporation as a scalable and efficient method for delivering CAR-T cells, achieving higher yields and viability compared to traditional methods.

Pooled screening identifies combinatorial CAR signaling domains for next-generation CAR-M immunotherapies

The paper identifies combinatorial CAR signaling domains that enhance macrophage function and tumor clearance through pooled screening and single-cell analysis.

Precise engineering of chimeric antigen receptor expression levels defines T cell identity and function

This study shows that varying CAR expression levels in T cells affects their activation, function, and transcriptional identity, with optimal CAR levels preventing exhaustion.

A novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity

This paper develops a PDPN- and GD2-targeting CAR T cell blend to overcome glioblastoma heterogeneity, showing improved anti-tumor activity in organoids and increased survival in mice.

Tumour-derived glucocorticoids amplify ROR1 and are exploited with glucocorticoid-resistant ROR1 CAR-T cells

The paper shows that tumor-derived glucocorticoids increase ROR1 expression while suppressing T cell activity, and GC-resistant CAR-T cells can overcome this by preserving ROR1 expression in tumor cells.

Tunneling CARs: Increasing CAR T tumor infiltration through the overexpression of MMP7 and SPP1

This study shows that overexpressing MMP7 and SPP1 improves GD2.CART infiltration into solid tumors, leading to better tumor control and survival in a xenograft model.

Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease

This paper develops bi-specific CAR-iNKT cells targeting CD19 and CD133 for KMT2A-rearranged leukemia, showing superior efficacy over CAR-T in eradicating leptomeningeal disease and inducing remission.

CAR T cell engineering impacts antigen-independent activation and co-inhibition

This study compares viral and non-viral methods for CAR T cell engineering, finding that non-viral SB transposition alters T cell activation and co-inhibition markers, with CAR design and donor type influencing outcomes.

Highly potent novel multi-armoured IL13Rα2 CAR-T subverts the immunosuppressive microenvironment of Glioblastoma

This paper develops a novel CAR-T cell therapy for glioblastoma that overcomes immunosuppression and improves persistence through a multi-armoured design.

Pluripotent stem cell-derived NK progenitor cell therapy prevents tumour occurrence and eradicates minimal residual disease

This study develops a novel CAR-NK cell therapy using pluripotent stem cell-derived NK progenitors that persist in blood and eliminate minimal residual disease.

Optimising CAR-T cell sensitivity by engineering matched extracellular sizes between CAR/antigen and CD2/CD58 adhesion complexes

The antigen sensitivity of CAR-T cells can be tuned to match the sensitivity of TCR-T cells by varying the relative extracellular size of CAR/antigen and CD2/CD58 complexes.

GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions

This paper shows that modifying T cells to use fructose via GLUT5 improves their anti-tumor activity in low-glucose environments.

Phosphotyrosine Signal Profiling of Clinical CAR-T Reveals Tonic Signaling Associated with Therapeutic Efficacy

This study uses phosphotyrosine proteomics to analyze CAR-T cells from patients and donors, finding heightened tyrosine phosphorylation and tonic signaling linked to therapeutic efficacy.